PDUFA VII Commitment Letter Outlines Real-Time Review Expansion, Hiring Goals
Executive Summary
Allergenic extract products, previously excluded, also will become part of the user fee program beginning in FY 2023.
You may also be interested in...
Long-Term Postmarket Studies For Gene Therapies May Need To Be Combined, Standardized
Running multiple product-specific postmarket trials for 15 years or longer would not be cost-effective and one industry stakeholder suggests workstreams eventually could merge.
Emerging Gene Therapy Concern: A Child Joins A Clinical Trial, But Must Be Followed Into Adulthood
The long-term follow-up requirements expected for many gene therapies could raise consent and drop-out issues, which could hinder efforts to track safety and efficacy.
Gene Therapy Sponsors Risk Additional Work With Late-Stage Manufacturing Changes
Commercial scale-up during Phase III trials could create labeling issues and force additional clinical trials, US FDA officials said.